Background {#Sec1}
==========

Women who have inherited mutations in *BRCA1* or *BRCA2* are at greatly increased risk of developing breast cancer (BC) and ovarian cancer (OC) \[[@CR25], [@CR38]\]. Identification of a mutation at these loci can lead to risk or mortality reduction if optimal surveillance, risk-reducing mastectomy (RRM), and risk-reducing salpingo-oophorectomy (RRSO) are applied \[[@CR8], [@CR29]\]. In addition, treatment of cancers in mutation carriers has advanced with the development of PARP inhibitors, which take advantage of the loss of *BRCA1/2* function in tumors \[[@CR37]\]. *BRCA1* and *BRCA2* are tumor suppressor genes, and tumors from the majority of mutation carriers have loss of heterozygosity (LOH), with loss of the normal allele, so there is no functioning protein \[[@CR6], [@CR7], [@CR13], [@CR31]\]. In early studies, including a small number of tumor samples obtained from large BC and OC families, it was suggested that greater than 85 % of *BRCA1-* or *BRCA2*-associated cancers exhibited LOH, and all showed loss of the normal allele.

The vast majority of *BRCA1* and *BRCA2* mutation carriers are single heterozygotes for *BRCA1* (SH1) or *BRCA2* (SH2). Homozygosity of missense alleles at *BRCA2* (*FANCD1*) leads to Fanconi Anemia and increased cancer susceptibility, notably hematological malignancies \[[@CR15], [@CR22]\]. At least three Fanconi Anemia cases are attributable to *BRCA2/FANCD1* homozygous mutations \[[@CR22]\]. Observations of homozygosity or compound heterozygosity at *BRCA1* are very rare. Domchek et al. \[[@CR9]\] reported a female patient with short stature, microcephaly, developmental delay, significant toxicity from chemotherapy, and epithelial ovarian carcinoma diagnosed at age 28 years. This woman was a compound heterozygote at *BRCA1*, with mutations c.2457delC (p.Asp821Ilefs\*25) and c.5207 T \> C (p.Val1736Ala). Both of these mutations are likely to be deleterious variants in *BRCA1*-associated cancer. The only other reported case of biallelic *BRCA1* mutations was in a woman with multiple congenital anomalies consistent with a Fanconi anemia-like disorder and breast cancer at age 23 \[[@CR30]\].

Transheterozygosity (TH) is the state of heterozygosity at two different loci. Here, we define TH to be inheritance of deleterious mutations in both *BRCA1* and *BRCA2*. Reports on several *BRCA1/2* transheterozygotes (TH) have been reported in the literature, mainly without further details on tumor or patient phenotype. Ramus et al. \[[@CR27]\] reported on one TH who had been diagnosed with both BC and OC, and was identified as having a mutation in *BRCA1* c.68_69delAG (185/187delAG) and *BRCA2* c.5946delT (6174delT). LOH in these tumors was not found. Additional reports identified TH for *BRCA1* c.2389G \> T and *BRCA2* c.3068dupA \[[@CR21]\], *BRCA1* c.68_69delAG and a *BRCA2* c.5946delT \[[@CR36]\], and TH with *BRCA1* c.68_69delAG and *BRCA2* c.5946delT \[[@CR11]\] in four cases. In addition, a number of reports of TH with LOH in cancer samples have been published. Randall et al. \[[@CR28]\] reported one TH identified with a *BRCA1* c.3770_3771delGA and *BRCA2* c.5946delT, and being affected with both BC and OC. For the BC, only LOH at the *BRCA1* locus was found (not at *BRCA2)*, and the OC sustained LOH at both *BRCA1* and *BRCA2*. Tesoriero et al. \[[@CR35]\] reported a TH with *BRCA1* c.3770_3771delGA and *BRCA2* c.5946delT. The BC of this patient lost the wild-type *BRCA2* allele. Bell et al. \[[@CR1]\] reported on a TH with c.5266dupC *BRCA1* and c.5946delT *BRCA2* mutation having three independent BCs. They showed that LOH occurred in two *BRCA2* and one *BRCA1* tumor. A large clinic-based series of 1191 carriers from Israel \[[@CR20]\] identified 16 TH females, 14 with the c.68_69delAG *BRCA1* and c.5946delT *BRCA2* mutations and two with the c.5266dupC *BRCA1* and c.5946delT *BRCA2* mutations. A study from Germany identified eight female TH from 8162 BC/OC families and compared the clinical characteristics of the TH to their SH relatives and to SH in the family-based study \[[@CR14]\].

To characterize the nature of TH and clinical phenotypes of TH, we used the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA) dataset of 32,295 female *BRCA1/2* mutation carriers ascertained in high-risk clinics and population-based studies. From this dataset, we investigated the occurrence of TH, we compared the characteristics and features of BC and OC in TH and single *BRCA1* or *BRCA2* mutations, and we examined LOH in as many cancer samples as possible.

Methods {#Sec2}
=======

Study sample {#Sec3}
------------

Details of CIMBA participating centers and data collection have been reported previously \[[@CR5]\]. All the included mutation carriers participated in clinical and research studies at the host institutions after providing informed consent under IRB-approved protocols. Fifty-five centers and multicenter consortia (Additional file [1](#MOESM1){ref-type="media"}: Table S1) submitted data that met the CIMBA inclusion criteria \[[@CR5]\]. Only female carriers with pathogenic *BRCA1/2* mutations, concerning TH, SH1, and SH2 mutation carriers, were included in the current analysis. Pathogenicity of mutation was defined as follows: 1) generating a premature termination codon (PTC), except variants generating a PTC in exon 27 after codon 3010 of *BRCA2*; 2) large in-frame deletions that span one or more exons; and 3) deletion of transcription regulatory regions (promoter and/or first exon) expected to cause lack of expression of mutant allele. We also included missense variants considered pathogenic by using multifactorial likelihood approaches \[[@CR4], [@CR12]\]. Mutations that did not meet the above criteria but have been classified as pathogenic by Myriad Genetics, Inc. (Salt Lake City, UT, USA) were also included.

Mutations are described using the Human Genome Variation Society (HGVS) nomenclature (<http://www.HGVS.org/varnomen>) where the nucleotide numbering is from the A of the ATG translation initiator codon. For deletions or insertions, the most 3′ position possible was arbitrarily assigned as the altered nucleotide. The description of mutations of all types is given at the genomic level (using cDNA reference sequences NM_007294.3/*BRCA1* and NM_000059/*BRCA2*). BIC nomenclature was also presented for common variants that are familiar to many researchers and clinicians by their BIC designation (<http://research.nhgri.nih.gov/bic>). For BIC nomenclature, cDNA sequences were used as reference sequence (Genbank: U14680/*BRCA1* and NM_000059.1/*BRCA2*). The nucleotide numbering is from nucleotide 1 of the cDNA gene sequence and for deletions or insertions the most 3′ position possible was arbitrarily assigned as the altered nucleotide.

In order to compare the TH with SH1 and SH2 mutation carriers on phenotypes of interest, we created a matched case--control set, in which "cases" were defined as TH, and "controls" were SH1 and SH2 mutation carriers. Matched SH1 "controls" carried a BRCA1 mutation found in the TH "case". Matched SH2 "controls" carried a BRCA2 mutation found in the TH "case". SH1 and SH2 were not matched to TH for any other characteristics. Using this approach, we identified 91 TH and 9316 matched SH1 mutation carriers, and 89 TH and 3370 matched SH2 mutation carriers.

Loss of heterozygosity {#Sec4}
----------------------

From 10 TH individuals, tumor tissue was available from twelve tumors, and blood DNA from 10 TH. From one case, tumor tissue from both BC and OC was available, and from another case affected with bilateral BC, tumor samples were available from both breast tumors. Hematoxylin and eosin (H&E) slides from each tumor were examined by a specialist pathologist. Areas of \>80 % tumor cells were marked for macro-dissection. DNA from two 10-micron unstained slides was extracted using the Qiagen QIAmp DNA FFPE Tissue Kit using the standard protocol but with 500 μl deparaffinization solution.

We performed micro-satellite analysis to objectively detect LOH as described previously \[[@CR16]\]. We amplified patient tumor and blood DNA for two markers within *BRCA1* (D17S855 and D17S1322) and four markers around *BRCA2* (D13S290, D13S260, D13S1698, and D13S171). The heterozygosity for these markers ranged from 0.46 to 0.82 \[[@CR17], [@CR26]\]. Primer sequences and distance from *BRCA1* or *BRCA2* are given in Additional file [1](#MOESM1){ref-type="media"} (Table S2). After polymerase chain reaction (PCR) amplification, samples were size-separated on a 96 capillary DNA analyzer (Applied Biosystems 3730xl). Data were analyzed using Genemapper Software (Applied Biosystems). For micro-satellites that were heterozygous, the ratios of allele peak heights for each tumor sample were compared to the allele peak heights for the blood DNA sample using the following formula L = (at2 X an1)/(at1 X an2), where L = the ratio; a = the height of the peak; n1 and n2 = normal allele 1 and normal allele 2; t1 and t2 = tumor allele 1 and tumor allele 2. All ten cases were informative for at least one marker in *BRCA1*. Where cases were informative for both markers, the LOH data were consistent for the two nearby markers. All ten cases were also informative for at least one of the four markers in *BRCA2*. In two cases, the data were not consistent across all markers in the 1.74 MB region and the data for the marker closest to *BRCA2* was used.

To complement the information obtained from micro-satellite analysis, we also undertook DNA sequence analysis. For each individual, a small region (\<200 bp) around each of their two mutations was PCR-amplified from both tumor and blood DNA. DNA from peripheral blood of a healthy control individual was also amplified for each fragment as a control for no mutation. We used 10 ng of DNA in the PCR reaction, using standard protocol and primer sequences (given in Additional file [1](#MOESM1){ref-type="media"}: Table S3). All three samples for each mutation were then treated with EXO-SAP-IT (Affymetrix) and Sanger sequenced using standard methods \[[@CR32]\]. This sequencing was used to confirm the presence of each mutation in the blood DNA from the patient and not in the control sample. We also assessed the mutation status in the tumor to determine if LOH had occurred. Since we extracted areas of \>80 % tumor cells, both alleles can be present even when LOH is present, due to contaminating normal tissue. Therefore, for each tumor we determined for each mutation if the two alleles were at an equal ratio compared to the germline sample or if there was a decrease in one of the two alleles.

Statistical Analysis {#Sec5}
--------------------

For comparison of TH and SH mutation carriers, contingency table analysis using a chi-square test was used for dichotomous variables, and a *t* test for continuous variables. Fisher's exact tests were used if sample sizes in any contingency table cell were less than five. Analyses were done in STATA, v. 13.1.

Results {#Sec6}
=======

Characteristics of TH versus SH1 and SH2 mutation carriers {#Sec7}
----------------------------------------------------------

Table [1](#Tab1){ref-type="table"} describes the 93 female TH from 84 families identified from the CIMBA database. Among the matched TH-SH1/SH2 sets, 25 had no cancer diagnosis. The average age of these women was 39 years and the average age at diagnosis of BC was 41 years. Only 16 women were less than age 41 and 9 women were over age 41 at the time of diagnosis (mean age 49.9, range 41.4--67.9). Table [2](#Tab2){ref-type="table"} shows that OC age for the matched BRCA1 TH cases was 51.1 years and SH1 controls was 50.9 years (*p* = 0.154). For the matched BRCA2 set the average OC age for the TH cases was 54.7 years and for SH2 controls was 56.8 years (*p* = 0.421) (Fig. [1](#Fig1){ref-type="fig"}).Table 1Transheterozygote *BRCA1 + BRCA2* mutations in 93 women*BRCA1* mutation*BRCA2* mutation*N*%Breast cancer onlyOvarian cancer onlyBreast + ovarian cancerNo cancerSelf-identified race/ethnicityCountry of ascertainmentHGVS: genomic levelHGVS: genomic level*n*%*n*%*n*%*n*%c.-19-?\_80 + ?dupc.8633-?\_8754 + ?amp\*11.111.100.000.000.0JewishHungaryc.68_69delAGc.5946delT3133.31313.911.133.21415.0Caucasian, Jewish, NRUSA, Hungary, Israelc.68_69delAGc.5722_5723delCT11.111.100.000.000.0CaucasianGermanyc.1016delAc.7379_7382delACAA11.111.100.000.000.0AsianUSAc.1390delA\*c.658_659delGT11.111.100.000.000.0HispanicUSAc.1504_1508del5c.2798_2799delCA11.111.100.000.000.0AsianKoreac.1504_1508del5c.462_463delAA11.100.000.011.100.0CaucasianGermanyc.1687C \> Tc.6469C \> T11.100.000.011.100.0CaucasianItalyc.1793 T \> ?c.8537_8538delAG11.100.000.011.100.0CaucasianUSAc.181 T \> Gc.1318_1319dupCT33.211.100.000.022.2CaucasianAustriac.211A \> Gc.4380_4381delTT11.111.100.000.000.0CaucasianUKc.212 + 1G \> Ac.739_740delAT\*11.111.100.000.000.0CaucasianSpainc.213-12A \> Gc.7180A \> T11.111.100.000.000.0CaucasianItalyc.2389G \> Tc.3068dupA11.111.100.000.000.0CaucasianCanadac.2405_2406delTGc.4284dupT11.100.000.011.100.0CaucasianItalyc.246delTc.517-2A \> G22.211.100.000.011.1CaucasianUKc.301 + 1G \> Ac.5682C \> G11.111.100.000.000.0CaucasianUSAc.3048_3052dup5c.2830A \> T22.211.100.000.011.1NRSwedenc.3155delAc.3160\_ 3163delGATA22.211.100.000.011.1CaucasianAustraliac.3196G \> T\*c.658_659delGT11.111.100.000.000.0CaucasianGermanyc.3228_3229delAGc.3689delC11.100.000.000.011.1CaucasianUKc.3228_3229delAGc.9253dupA11.111.100.000.000.0CaucasianItalyc.3400G \> Tc.2808_2811delACAA22.211.100.000.011.1CaucasianUKc.3477_3480 delAAAGc.9401delG11.100.011.100.000.0CaucasianItalyc.3627dupAc.6724_6725delGA11.111.100.000.000.0AsianKoreac.3700_3704del5c.681 + 1G \> A11.111.100.000.000.0CaucasianAustraliac.3700_3704del5c.1815dupA11.111.100.000.000.0CaucasianGermanyc.3756_3759delGTCTc.7757G \> A11.111.100.000.000.0CaucasianUSAc.3759_3760delTAc.9699_9702 delTATG11.100.000.011.100.0HispanicUSAc.3770_3771delAGc.5946delT22.211.100.011.100.0NR, JewishAustralia, USAc.3839_3843 delinsAGGCc.1636delT22.200.011.100.011.1NRFrancec.390C \> Ac.3018delA11.111.100.000.000.0AsianKorea3910delGc.2830A \> T11.111.100.000.000.0CaucasianGermanyc.3916_3917delTTc.5380delG\*11.100.000.011.100.0CaucasianItalyc.4035delAc.658_659delGT11.100.000.000.011.1CaucasianAustraliac.4065_4068delTCAAc.5350_5351delAA11.111.100.000.000.0CaucasianUSAc.4186-?\_4357 + ?dupc.2636_2637delCT22.211.100.000.011.1CaucasianUKc.427G \> Tc.8730delT11.111.100.000.000.0CaucasianDenmarkc.5030_5033 delCTAAc.1399A \> T11.111.100.000.000.0AsianKoreac.5123C \> Ac.6275_6276delTT11.111.100.000.000.0CaucasianGermanyc.5136G \> Ac.4965delC11.111.100.000.000.0AsianUSAc.5193 + 1delGc.658_659delGT11.100.011.100.000.0CaucasianGermanyc.5251C \> Tc.6753_6754delTT11.111.100.000.000.0CaucasianAustriac.5266dupCc.8364G \> A11.111.100.000.000.0CaucasianAustriac.5266dupCc.5946delT55.433.200.011.111.1JewishUK, Israelc.5266dupCc.4478_4481delAAAG11.111.100.000.000.0CaucasianGermanyc.5266dupCc.5645C \> A11.100.000.011.100.0CaucasianGermanyc.5406 + 664\_\*8273delc.9748dupT11.111.100.000.000.0CaucasianGreecec.548-?\_4185 + ?delc.2269A \> T\*11.100.000.011.100.0CaucasianGermanyc.962G \> Ac.2231C \> G11.111.100.000.000.0CaucasianGermanyTotal931005154.844.31314.02526.9Mean age (range)39.9 (23--67)59.2 (57--62)41.9 (26--53)39.1 (20--68)\*Not included in the matched analysis because one of the mutations found in the TH was not found among the SH1/SH2 carriers*HGVS* Human Genome Variation Society, *NR* not reported Table 2Description of *BRCA1, BRCA2*, and transheterozygote *BRCA1 + BRCA2* mutation carriersVariableValue*BRCA1 + BRCA2 (TH)N(%)BRCA1 (SH1)N(%)P* value\**P* value\**BRCA1* + *BRCA2 (TH) N(%)BRCA2 (SH2)N(%)P* value\*\**P* value\*\*Total matched919316893370Year of birth\<1940\
1941--1950\
1951--1960\
1961--1970\
\>19705 (5.5)\
20 (22.0)\
21 (22.6)\
27 (29.0)\
18 (19.8)886 (9.5)\
1628 (17.4)\
2607 (28.0)\
2409 (25.9)\
1779 (19.0)0.424(ref)\
0.112\
0.474\
0.153\
0.2455 (5.6)\
19 (21.3)\
19 (21.3)\
27 (30.3)\
19 (21.3)486 (14.4)\
735 (21.8)\
914 (27.1)\
724 (21.5)\
511 (15.2)**0.025**(ref)\
0.060\
0.156\
**0.005**\
**0.007**EthnicityWhite\
African American\
Asian\
Hispanic\
Jewish\
Other47 (51.6)\
0 (0)\
6 (6.6)\
1 (1.1)\
30 (33.0)\
7 (7.7)5736 (61.6)\
20 (0.2)\
82 (0.9)\
143 (1.5)\
1779 (19.1)\
1556 (16.7)**\<0.001**(ref)\
1.00\*\
**\<0.001**\
1.00\
**0.002**\
\--45 (50.6)\
0 (0)\
6 (6.7)\
2 (2.2)\
29 (32.6)\
7 (7.9)1686 (50.0)\
15 (0.4)\
66 (2.0)\
57 (1.7)\
936 (27.8)\
610 (18.1)**0.007**(ref)\
1.00\*\
**0.004**\
0.667\
0.573\
**\--**Breast cancerNo\
Yes29 (31.9)\
62 (68.1)4470 (48.0)\
4846 (52.0)**0.002**29 (32.6)\
60 (67.4)1671 (49.6)\
1699 (50.4)**0.002**Age of breast cancerMean (range)40.4 (23--67)41.9 (18--82)0.23140.5 (23--67)45.0 (19--82)**\<0.001**Ovarian cancerNo\
Yes74 (81.3)\
17 (18.7)7766 (83.4)\
1550 (16.6)0.60374 (83.1)\
15 (16.9)3056 (90.7)\
314 (9.3)**0.017**Age of ovarian cancerMean (range)54.1 (36--66)50.9 (20--85)0.15454.7 (42--66)56.8 (26--89)0.421Bilateral mastectomyNo\
Yes58 (63.7)\
8 (9.0)4807 (51.6)\
809 (8.7)0.59958 (65.2)\
8 (9.0)1856 (55.0)\
305 (9.1)0.646Prophylactic oophorectomyNo\
Yes45 (49.5)\
24 (26.4))3583 (38.4)\
2476 (26.6)0.30745 (50.6)\
24 (27.0)1388 (41.2)\
980 (29.1)0.272Follow up age (if no cancer)Mean (range)39.1 (20--68)40.5 (18--99)0.58739.1 (20--68)44.1 (18--94)0.068\*Matched *BRCA1* mutation carriers vs *BRCA1 + BRCA2* mutation carriers; \*\*matched *BRCA2* mutation carriers vs *BRCA1 + BRCA2* mutation carriersSignificant *p* values are shown in bold type Fig. 1Age of breast and ovarian cancer diagnosis by mutation status

The most common TH involved inheritance of two of the three common Jewish mutations: 5 (5.4 %) women inherited *BRCA1* c.5266dupC and *BRCA2* c.5946delT; 31 (33.3 %) women inherited *BRCA1* c.68_69delAG and *BRCA2* c.5946delT. Six (6.5 %) women carried one of the three common Jewish mutations and another mutation. The majority of the remaining TH were observed only once. The majority of the TH self-identified as non-Hispanic Caucasian or Jewish. Of the 6907 women who carried one of the Jewish founder mutations, 2732 (39.6 %) self-identified as Jewish, 947 (13.7 %) were unknown, and 3225 (46.7 %) reported an ethnicity other than Jewish. We observed two TH in Hispanics and six TH in Asians (four of which were Korean). Of the 93 TH, 51 were diagnosed with BC only, 4 with OC only, 13 with both BC and OC, and 25 with no cancer diagnosis.

The matched datasets included 91 TH and 9316 SH1 for the *BRCA1* matched analysis, and 89 TH and 3370 SH2 for the *BRCA2* matched analysis. Two *BRCA1* mutations were observed among the TH in our dataset that were not observed among SH1 (c.1390delA and c.3196G \> T), and four *BRCA2* mutations were observed in the TH dataset that were not observed among the SH2 (c.8633-?\_8754 + ?amp, c.739_740delAT, c.5380delG, and c.2269A \> T). These six carriers were not included in the analysis (denoted by asterisk in Table [1](#Tab1){ref-type="table"}). TH were more likely to be born more recently (i.e., since 1961) than SH2 mutation carriers but not when compared to SH1s (Table [2](#Tab2){ref-type="table"}). The TH group consisted of more individuals from Asian ancestry compared to the SH1 and SH2 groups, with an excess of women having a Jewish ancestry vs. the SH1 group. TH were more likely to have ever been diagnosed with BC than SH1 or SH2 individuals (68.1 % vs. 52.0 %; *p* = 0.002, and 67.4 % vs. 50.4 %; *p* = 0.002), and TH were more likely to be diagnosed with OC than SH2 women (16.9 % vs. 9.3 %; *p* = 0.017), which was not observed in TH vs. SH1 women, perhaps due to the lower incidence of OC in *BRCA2* vs. *BRCA1*. Age at BC diagnosis was significantly different for TH vs. SH2 (40.5 years vs. 45.0 years; *p* \< 0.001), but there was no difference between TH and SH1.

There were 64 TH cases with BC. Of these, 62 TH were matched to 4846 SH1s and 60 TH were matched to 1699 SH2 (Table [3](#Tab3){ref-type="table"}). TH were more likely to have estrogen receptor (ER)- and progesterone receptor (PR)-positive BC than SH1s (ER: 42.9 % vs. 24.0 %; *p* = 0.010; PR: 40.6 % vs. 20.0 %; *p* = 0.013). In contrast, the BCs of TH were less likely ER- and PR-positive than in SH2s (ER: 42.9 % vs. 76.5 %; *p* \< 0.0001; PR: 40.6 % vs. 62.8 %; *p* = 0.012). The proportion of ER- and PR-positive BCs in TH was intermediate to that of SH1 and SH2. No difference was seen regarding the HER2 status between the BCs of TH and SH1s and SH2s, respectively, although the available numbers were small. No differences in other BC characteristics (morphology, grade, stage) were observed.Table 3Breast tumor characteristics of *BRCA1, BRCA2,* and transheterozygote *BRCA1 + BRCA2* mutation carriersTraitValue*BRCA1 + BRCA2 (TH) N(%)BRCA1 (SH1) N(%)P* value*BRCA1 + BRCA2 (TH) N(%)BRCA2 (SH2) N(%)P* value*N*624846601699HER2Negative14 (93.3)908 (88.7)1.0015 (93.8)274 (86.2)0.706Positive1 (7.7)116 (11.3)1 (6.3)44 (13.8)PRNegative19 (59.4)1260 (80.0)**0.013**19 (59.4)215 (37.2)**0.012**Positive13 (40.6)356 (20.0)13 (40.6)363 (62.8)ERNegative20 (57.1)1347 (76.0)**0.010**20 (57.1)150 (23.5)**\<0.0001**Positive15 (42.9)424 (24.0)15 (42.9)487 (76.5)Nodal statusNegative20 (66.7)1197 (65.1)0.85419 (65.5)399 (61.3)0.647Positive10 (33.3)643 (35.0)10 (34.5)252 (38.7)GradeWell differentiated2 (7.1)36 (2.3)0.1612 (7.1)36 (6.4)0.690Moderately differentiated8 (28.8)342 (22.1)8 (28.8)207 (36.6)Poorly/undifferentiated18 (64.3)1172 (75.6)18 (64.3)322 (57.0)Stage01 (4.8)34 (3.6)0.5411 (4.6)48 (13.9)0.06517 (33.3)399 (42.2)7 (31.8)123 (35.7)213 (61.9)440 (46.6)14 (63.6)124 (35.9)30 (0)65 (6.9)0 (0)36 (10.4)40 (0)7 (0.7)0 (0)14 (4.1)MorphologyDuctal26 (70.3)1544 (74.3)0.34527 (73.0)629 (78.8)0.359Lobular3 (8.1)61 (2.9)3 (8.1)70 (8.8)Medullary3 (8.1)173 (8.3)2 (5.4)13 (1.6)Other5 (13.5)301 (14.5)5 (13.5)86 (10.8)Number of positive nodes (SD)2 (6.1)1.2 (3.4)0.2152.1 (6.2)1.7 (3.9)0.627Tumor size (SD)19.0 (14.9)18.3 (12.5)0.77519.0 (14.9)19.2 (14.6)0.932Significant *p* values are shown in bold type*ER* estrogen receptor, *PR* progesterone receptor, *SD* standard deviation

Only 17 TH were diagnosed with OC, and thus we had limited data on features of OC to make inferences regarding differences in TH compared with SH1 or SH2. No statistically significant differences were observed for OC traits between TH and SHs (Table [4](#Tab4){ref-type="table"}). Surprisingly, four borderline tumors were reported in both the SH1 and SH2 groups.Table 4Ovarian tumor characteristics of *BRCA1, BRCA2,* and transheterozygote *BRCA1 + BRCA2* mutation carriersTraitValue*BRCA1 + BRCA2 (TH)N(%)BRCA1 (SH1)N(%)P* value*BRCA1 + BRCA2 (TH)﻿N(%)BRCA2 (SH2)N(%)P* value*N*17155015314GradeWell differentiated08 (2.8)0.93004 (6.2)0.847Moderately differentiated1 (25)60 (20.8)1 (25)12 (18.5)Poorly/undifferentiated3 (75)220 (76.4)3 (75)49 (75.4)Stage1039 (17.4)0.60006 (13.3)0.58921 (33.3)31 (13.8)1 (33.3)5 (11.1)32 (66.7)120 (53.6)2 (66.7)28 (62.2)4034 (15.2)06 (13.3)MorphologySerous5 (83.3)292 (66.8)0.9055 (83.3)71 (73.2)0.943Mucinous04 (0.9)02 (2.0)Endometroid044 (10.1)07 (7.2)Clear cell06 (1.4)02 (2.0)Other1 (16.7)91 (20.8)1 (16.7)15 (15.5)BehaviorInvasive7 (100)449 (99.1)0.8036 (100)89 (95.7)0.604Borderline04 (0.9)04 (4.3)

Loss of heterozygosity {#Sec8}
----------------------

Due to the frequent LOH in SH individuals, we examined the hypothesis that either *BRCA1* or *BRCA2* would be lost in each of the TH individuals due to LOH, and that whichever gene was lost could have an impact on their tumor characteristics. Of the 68 TH individuals with cancer, LOH analysis of three tumors from two cases had previously been published by our group using the same methods as the newly identified cases \[[@CR27]\]. In the context of the current study, 12 additional tumor samples from 10 patients were analyzed (Table [5](#Tab5){ref-type="table"}). We first used micro-satellite markers and an objective ratio of peak heights to determine if there was loss of one of the alleles when an individual was heterozygous \[[@CR3]\] (Additional file [1](#MOESM1){ref-type="media"}: Tables S4 and S5). LOH analysis with micro-satellite markers normally includes linkage or segregation data to determine if the normal allele is lost. Since we did not have samples from other family members, we performed Sanger sequencing at the position of the mutations in both germline and tumor samples to determine which allele was lost. One sample failed for the sequencing so it was not possible to determine whether the normal or mutated allele was lost. Some samples showed loss of the mutant allele, which would suggest random loss. Tumors that exhibited LOH by micro-satellite analysis but did not indicate a decrease of the normal allele by sequencing were not considered to exhibit classic LOH. Following both sets of analyses and including our previously published data, one breast tumor (case 8) and one OC (case 2) showed LOH for *BRCA1*, two breast tumors (cases 9 and 11) showed LOH of *BRCA2*, and the remaining tumors provided no evidence for LOH at either *BRCA1* or *BRCA2* (Table [5](#Tab5){ref-type="table"}).Table 5Loss of heterozygosity in tumor tissueLOH in breast tumorLOH in ovarian tumorCaseDiagnosisTissue studied*BRCA1* mutation*BRCA2* mutationMicro-satellite DataSequence dataInferenceMicro-satellite dataSequence dataInference1DCISDCISc.5136G \> Ac.4965delC*BRCA1, BRCA2*NoNo LOH2BreastInv Brc.1793 T \> Ac.8537_8538delAG*BRCA2BRCA1*No LOH3Invasive breastInv Brc.68_69delAGc.5946delT*BRCA1*NoNo LOH5Invasive breastDCIS^b^c.181 T \> Gc.1318_1319dupCTNo*BRCA2*No LOH6 LBilateral breastDCIS^b^c.5251C \> Tc.6753_6754delTTNoNoNo LOH^d^6RBilateral breastDCIS^b^c.5251C \> Tc.6753_6754delTT*BRCA1*NoNo LOH^d^7Invasive breastDCIS^b^c.5266dupCc.8364G \> ANo*BRCA1*No LOH8Invasive breastDCIS^b^c.3700_3704del5c.681 + 1G \> A*BRCA1, BRCA2BRCA1BRCA1* LOH9Invasive breastDCIS^b^c.68_69delAGc.5946delT*BRCA2BRCA1, BRCA2BRCA2* LOH10Invasive breastInv Brc.68_69delAGc.5946delT*BRCA1, BRCA2*FailedFailed^c^11^a^Invasive breastInv Brc.3770_3771delAGc.5946delT^aa^*BRCA2* LOH12^a^BreastInv Brc.68_69delAGc.5946delT^aa^No LOH2OvaryOvc.1793 T \> Ac.8537_8538delAG*BRCA1BRCA1BRCA1* LOH4OvaryOvc.68_69delAGc.5946delTNoNoNo LOH12^a^OvaryOvc.68_69delAGc.5946delT^aa^No^aa^No LOHSee also Additional file [1](#MOESM1){ref-type="media"} (Table S5)^a^Previously published, ^b^with micro-invasion, ^c^case failed due to no PCR amplification in the sequencing, ^d^no LOH in either the right or left breast tumor*DCIS* ductal carcinoma *in situ*, *Inv Br* invasive breast cancer, *LOH* loss of heterozygosity, *Ov* ovarian cancer

Discussion {#Sec9}
==========

This study describes the characteristics of TH compared with SH1 and SH2 mutation carriers and supplements the existing literature regarding LOH in TH. Previously, 35 female TH individuals have been reported in the literature in a series of papers \[[@CR1], [@CR11], [@CR14], [@CR20], [@CR21], [@CR27], [@CR28], [@CR35], [@CR36]\]. Only three relatively small studies have so far compared the characteristics of TH to SH women. Lavie et al. \[[@CR20]\] reported a non-significant difference in BC occurrence; seven of the 16 TH women (46.7 %) had a personal history of breast carcinoma compared with 372 of 926 (40.2 %) carriers of a single mutation (odds ratio (OR) = 1.3, 95 % confidence interval (CI) 0.4--4.0) \[[@CR20]\]. The mean age at diagnosis in TH was 44.6 years, compared with 48.1 in SH. In contrast, Heidemann et al. \[[@CR14]\] based on a study of 8 TH individuals suggested that TH develop BC at an earlier age and have more severe disease than those with single heterozygous *BRCA* mutation \[[@CR14]\]. Zuradelli et al. \[[@CR39]\] reported TH, and provided the possible association between TH and gastric cancer. Similar to the results from the study by Lavie et al. on 16 Ashkenazi Jewish female TH \[[@CR20]\], we report that TH were more likely than both SH1 or SH2 to be diagnosed with BC, which was also observed in our series. In addition to prior reports, we observed that TH were more likely to be diagnosed with OC compared with SH2s, but not compared with with SH1s. TH breast tumors were more likely to be ER-/PR-positive than in SH1, but less likely than in SH2 patients, without other different tumor or disease characteristics.

A number of TH had not been diagnosed with cancer by the time this analysis was completed. Twenty-five TH in our cohort had no BC or OC diagnosis at the time of counseling or genotyping. The average age of these TH individuals was 39.1 years (range 20--68). Of these, 16 (64 %) were less than 41 years old at the time of study, which is the average age of BC diagnosis, and 23 (92 %) were younger than the average age of OC diagnosis (54 years) in the CIMBA data. Of these 25 unaffected TH women, 7 (28 %) reported a RRSO compared to 2751 (22.6 %) who underwent RRSO among the total set of SH controls without BC or OC (12,154). Two (8.0 %) cancer-free TH underwent bilateral risk-reducing mastectomy compared to 1076 (8.9 %) SH. In addition, we had missing data for a number of relevant variables that could have impacted some inferences. For example, of the 62 breast cancers in the TH groups, only 21 (34 %) reported stage information.

Although this is the largest series of TH women reported to date, the study is still limited in a number of ways. TH were more likely to be born more recently (i.e., since 1961) than SH2, but not SH1. Since there is evidence that birth cohort may have an important effect on cancer risk \[[@CR18]\], the risk associations reported here may require additional evaluation in the future. The higher incidence of BC in the TH group versus both SH1 and SH2 groups, and of OC in the TH vs. the SH2 cohort could be explained by non-random inclusion of TH in the sample, leading to potential biases in associations, and this may limit generalizability of the dataset. Our analyses also do not account for potentially important confounders and the longitudinal nature of the data to follow cancer cases from time of testing to either cancer diagnosis or censoring after risk-reducing surgery. Furthermore, the great majority of missing data on cancer features avoids that certain questions may be appropriately addressed from this type of dataset. Additional future studies are required to completely evaluate these clinically important unresolved issues, and hopefully with the ongoing multinational collaboration within consortia like CIMBA this will be possible in time.

Differences in breast tumor hormone receptor status suggest that TH cases developing BC have an intermediate cancer phenotype between *BRCA1* and *BRCA2*, which would be consistent with the tumors being driven by loss of either *BRCA1* or *BRCA2*. We attempted to determine the frequency of loss of each gene in a subset of cases where tumor material was available. Previously published data suggest a high rate of LOH with loss of the normal allele in the majority of BRCA1 and BRCA2 cases with strong family history at approximately 80 and 70 years, respectively \[[@CR24]\]. However, we did not find loss of either *BRCA1* or *BRCA2* in the majority of tumors. The low frequency of LOH was consistent with the results from a previously published case (case 12) where we did not find LOH of either gene in either the breast or ovarian tumor \[[@CR27]\]. Three other papers on TH showed LOH with loss of the normal allele \[[@CR1], [@CR28], [@CR35]\]. One potential reason for the low frequency of LOH in this study could be that seven of the breast tumor samples were areas of ductal carcinoma *in* situ (DCIS) with micro-invasion rather than a region of the invasive breast tumor. However, we identified two tumors with LOH in these types of samples so this explanation is unlikely to be the major cause of the low rate of LOH.

The observed ages at diagnosis of BC in TH, SH1, and SH2, and the distributions of tumor characteristics may also reveal the interactions of *BRCA1* and *BRCA2* mutations, which may have implications for modeling the cancer susceptibility in TH. The observed age distributions rule out a multiplicative model for the interactions of *BRCA1* and *BRCA2* mutations on BC risk. Given the well-established BC risks for *BRCA1* and *BRCA2* mutations, a multiplicative model would imply very high cancer risk at young ages. However, the present study suggests that ages at BC diagnosis in TH are not significantly different from those in *BRCA1* mutation carriers. Therefore, a multiplicative model of cancer risk for *BRCA1* and *BRCA2* is inconsistent with the current observations. This observation, combined with the fact that the tumor characteristics are intermediate to SH1 and SH2, suggests that an additive model for the joint effects of *BRCA1* and *BRCA2* mutations is more plausible. These results could be used for modeling the cancer risks for TH carriers and could be incorporated into risk prediction models.

Micro-satellite analysis alone did show a decrease in one of the two alleles in more of the tumors (6 out of 12 *BRCA1* and 5 out of 12 *BRCA2*); however, the sequencing data suggested that the mutant allele rather than the normal allele was lost in many of the tumors. Although the early publications in high-risk families showed very high rates of LOH, exclusively with loss of the normal allele, more recently there have been many publications showing larger numbers of cases with no LOH \[[@CR19], [@CR23], [@CR24]\] and an increasing number of tumors with loss of the mutant allele \[[@CR19], [@CR24]\]. The second hit in these tumors could be due to a somatic mutation of the normal chromosome or due to promoter methylation, rather than LOH. Unfortunately, the amount of material from these tumors was very limited, and it was not possible to preform additional experiments to investigate alternative mechanisms. Methylation of *BRCA1* has been shown to be a mechanism of decreased *BRCA1* expression in sporadic BC \[[@CR2], [@CR34]\], although this is less frequent in *BRCA1* carriers \[[@CR10], [@CR33]\]. Why the mechanism of LOH with loss of the normal allele in TH might be different compared with SH is unclear. Tumor material was only available in a small proportion of the cases with cancer. Therefore, it is difficult to interpret the results of the tumor study more broadly. Despite the small numbers, we did not find evidence to support the hypothesis that the tumors would either have LOH of *BRCA1* or *BRCA2*. The TH breast tumor characteristics, however, do appear to be intermediate in phenotype to SH1 and SH2, suggesting some cancers are being driven by inactivation of *BRCA1* and some by inactivation of *BRCA2*. Additional studies that explore other causes of inactivation (e.g., methylation or somatic mutation) are warranted.

Conclusions {#Sec10}
===========

We report evidence that the *BRCA1* mutation in TH may drive these clinical TH phenotypes based on elevated OC risk in TH vs. SH2 but not SH1, and earlier age of BC diagnosis in TH vs. SH2 but not SH1. Therefore, TH may be managed more like BRCA1 mutation carriers than BRCA2 mutation carriers. In contrast, TH breast tumor characteristics (e.g., ER/PR status) are intermediate in phenotype to SH1 and SH2. Future studies are warranted to understand whether TH should be managed differently to SH1 or SH2 carriers, and, if so, to enable individualized counseling and clinical management appropriate for TH mutation carriers.
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Additional file 1: Table S1.Ethics committees that granted approval for the access and use of the data for this study. **Table S2.** Participant counts by center and mutation. **Table S3.** Primers used for PCR and Sanger sequencing. **Table S4.** Primers used in micro-satellite analysis for loss of heterozygosity. **Table S5.** Micro-satellite loss of heterozygosity and sequencing analysis results. (DOC 177 kb)
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